Koch Disruptive Technologies (KDT), a corporate venturing subsidiary of chemicals and energy conglomerate Koch Industries, led a $215m series B round for US-based biotech data provider Immunai yesterday.
Alexandria Venture Investments, the venture capital subsidiary of life sciences and property investment trust Alexandria Real Estate Equities, also took part in the round, as did Talos VC, 8VC, Piedmont, Icon and unnamed other investors that included existing shareholders.
Immunai is developing an artificial intelligence and machine learning-equipped clinical database with immunological information that helps users discover and develop immunotherapies. It has now raised $295m since it was founded in 2018.
The company had closed a $60m series A round in February this year co-led by pharmaceutical firm Dexcel Pharma, Schusterman Family Investments, Duquesne Family Office and Catalio Capital Management.
The round was also backed by Viola Ventures and TLV Partners, the last two having co-led Immunai’s $20m seed round nine months before.
Eli Groner, managing director for KDT, is joining Immunai’s board of directors in connection of the deal. He said: “Immunai is leaving no stone unturned in understanding and developing technology to map the immune system – critical scientific work that will give us greater knowledge to treat diseases and improve patient outcomes.
“We invested in Immunai because we recognise that understanding the immune system and its incredible complexity is key for the future of medicine.”